Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre

References

• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222.
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32(10):920–928.
   PubMed Web of Science ®Google Scholar
• McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207–216.
   PubMedGoogle Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Wisniowski B, Wechalekar A. Confirming the diagnosis of amyloidosis. Acta Haematol. 2020;143(4):312–321.
   PubMed Web of Science ®Google Scholar
• Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castaño A, Pozniakoff T, et al. (99m) Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.
   PubMed Web of Science ®Google Scholar
• Staron A, Connors LH, Zheng L, et al. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10(11):118.
   PubMed Web of Science ®Google Scholar
• Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018;270:192–196.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program. 2020;2020(1):380–388.
   PubMedGoogle Scholar
• Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis. Semin Neurol. 2019;39(5):578–588.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983;143(8):1549–1552.
   PubMedGoogle Scholar
• van Gameren II, Hazenberg BPC, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015–2021.
   PubMedGoogle Scholar
• El-Meanawy A, Mueller C, Iczkowski KA. Improving sensitivity of amyloid detection by Congo red stain by using polarizing microscope and avoiding pitfalls. Diagn Pathol. 2019;14(1):57.
   PubMedGoogle Scholar
• Elghetany MT, Saleem A, Barr K. The congo red stain revisited. Ann Clin Lab Sci. 1989;19(3):190–195.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol. 1999;309:3–25.
   PubMed Web of Science ®Google Scholar
• Röcken C, Sletten K. Amyloid in surgical pathology. Virchows Arch. 2003;443(1):3–16.
   PubMed Web of Science ®Google Scholar
• Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723–1727.
   PubMed Web of Science ®Google Scholar
• Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905–1908.
   PubMed Web of Science ®Google Scholar
• Staron A, Connors LH, Ruberg FL, et al. A new era of amyloidosis: the trends at a major US referral Centre. Amyloid. 2019;26(4):192–196.
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Gabrovsek A, Sul L, et al. Evidence of concurrent light chain and transthyretin cardiac amyloidosis in 2 patients. JACC CardioOncol. 2020;2(1):127–130.
   PubMedGoogle Scholar
• Castano A, Haq M, Narotsky DL, et al. Multicenter Study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880–889.
   PubMed Web of Science ®Google Scholar
• Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45(11):1945–1955.
   PubMed Web of Science ®Google Scholar
• Hanna M, Ruberg FL, Maurer MS, et al. Cardiac Scintigraphy with technetium-99m-Labeled Bone-Seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75(22):2851–2862.
   PubMed Web of Science ®Google Scholar
• Alreshq R, Cozzolino M, Lilleness B, et al. Light Chain testing abnormalities among patients with transthyretin amyloid cardiomyopathy referred for technetium-99m pyrophosphate imaging. Am J Cardiol. 2022;181:105–112.
   PubMed Web of Science ®Google Scholar
• Asif T, Gomez J, Singh V, et al. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: perils and pitfalls. J Nucl Cardiol. 2021;28(1):104–111.
   PubMed Web of Science ®Google Scholar
• Chimenti C, Alfarano M, Maestrini V, et al. False‐positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy. ESC Heart Fail. 2021;8(4):3387–3391.
   PubMed Web of Science ®Google Scholar
• Wehbe RM, Kansal P, Holly TA. Cases from a busy nuclear cardiology laboratory: potential pitfalls in the interpretation of cardiac scintigraphy for ATTR cardiac amyloidosis. J Nucl Cardiol. 2021;28(2):653–660.
   PubMed Web of Science ®Google Scholar
• Masri A, Bukhari S, Ahmad S, et al. Efficient 1-Hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2020;13(2):e010249.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Ruberg FL. Cardiac Scintigraphy and screening for transthyretin cardiac amyloidosis: caveat emptor. Circulation. 2021;144(13):1005–1007.
   PubMed Web of Science ®Google Scholar